echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hengrui Cyclophosphamide Capsules intends to give priority to review while 2 new drugs are approved for clinical trials

    Hengrui Cyclophosphamide Capsules intends to give priority to review while 2 new drugs are approved for clinical trials

    • Last Update: 2021-11-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Rubik's Cube Info

    Author: Sunshine

    Recently, the CDE official website showed that Hengrui cyclophosphamide capsules are planned to be included in the priority review and are suitable for the treatment of lymphoma, leukemia, neuroblastoma, ovarian adenocarcinoma, retinoblastoma, breast cancer and many other tumor types


    At the same time, the default license of the CDE clinical trial shows that the clinical application of two new drugs of Shengdia has been approved by the National Food and Drug Administration.


    Cyclophosphamide capsule is a DNA alkylating agent and cytotoxic immunosuppressant.


    Cyclophosphamide was developed by BAXTER and was approved by the FDA in 1959 (cyclophosphamide tablets and cyclophosphamide injections), and has now been withdrawn from the market


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.